Pharmaceuticals, Biotechnology and Life Sciences
ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.
Barentz, a leading global specialty ingredients solutions provider, has appointed Derk Jan Terhorst Group Chief Executive Officer, effective 1 January 2025, who will take over from Terry Hill who served as Interim CEO since May 2024.
Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.
Alliance Healthcare UK has appointed Paula Sutherland to the position of Sales Director where she will lead sales teams in…
Clinigen, the global pharmaceutical services company, today announces it has signed an exclusive supply and distribution agreement with Santhera Pharmaceuticals (SIX:…
Italian clinical-stage oncology company BetaGlue Therapeutics, developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, announced Monday that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m.
Novo Nordisk announced Monday it plans to invest 8.5 billion Danish kroner (€1.14B) to establish a completely new production facility in Odense, Denmark.
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
Italian Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and Japanese EA Pharma, a subsidiary of Eisai Co., Ltd., have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories.
Each unit is being sold at an effective offering price of $5.85 per unit, priced at-the-market under Nasdaq rules.